JCO Early Release, published online ahead of print Jan 22 2007
Journal of Clinical Oncology, 10.1200/JCO.2006.09.2403
Received September 18, 2006
Accepted December 20, 2006
Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson,* Beate Pfistner, Malik E. Juweid, Randy D. Gascoyne, Lena Specht, Sandra J. Horning, Bertrand Coiffier, Richard I. Fisher, Anton Hagenbeek, Emanuele Zucca, Steven T. Rosen, Sigrid Stroobants, T. Andrew Lister, Richard T. Hoppe, Martin Dreyling, Kensei Tobinai, Julie M. Vose, Joseph M. Connors, Massimo Federico, and Volker Diehl
From the Division of Hematology/Oncology, Georgetown University Hospital, Washington, DC; University of Cologne, Cologne; Department of Nuclear Medicine, University of Iowa, Iowa City, IA; Department of Pathology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada; Department of Oncology and Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark; Division of Oncology and Department of Radiation Oncology, Stanford University, Stanford, CA; Department of Hematology, Hospices Civils de Lyon and Université Claude Bernard, Lyon, France; James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; Academic Medical Center, Department of Hematology, Amsterdam, the Netherlands; Lymphoma Unit, Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Lurie Cancer Center, Northwestern University, Chicago, IL; Department of Nuclear Medicine, University Hospital Gasthuisberg, Leuven, Belgium; Cancer Research UK Medical Oncology Unit, St Bartholomew's Hospital, London, United Kingdom; Department of Medicine III, University of Munich, Hospital Grosshadern, Munich, Germany; Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan; Section of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE; and Dipartimento di Oncologia ed Ematologia, Università di Modena e Reggio Emilia, Modena, Italy.
* To whom correspondence should be addressed. E-mail: bdc4{at}georgetown.edu
Purpose: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies.
Methods: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations.
Results: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided.
Conclusion: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
H. Mocikova, P. Obrtlikova, B. Vackova, and M. Trneny
Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study
Ann. Onc.,
November 9, 2009;
(2009)
mdp522v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Fernandez de Larrea, C. Martinez, A. Gaya, A. Lopez-Guillermo, M. Rovira, F. Fernandez-Aviles, M. Lozano, F. Bosch, J. Esteve, B. Nomdedeu, et al.
Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation
Ann. Onc.,
November 4, 2009;
(2009)
mdp487v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Ennishi, H. Asai, Y. Maeda, K. Shinagawa, K. Ikeda, M. Yokoyama, Y. Terui, K. Takeuchi, T. Yoshino, K. Matsuo, et al.
Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
Ann. Onc.,
November 2, 2009;
(2009)
mdp490v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Jacene, S. Leboulleux, S. Baba, D. Chatzifotiadis, B. Goudarzi, O. Teytelbaum, K. M. Horton, I. Kamel, K. J. Macura, H.-L. Tsai, et al.
Assessment of Interobserver Reproducibility in Quantitative 18F-FDG PET and CT Measurements of Tumor Response to Therapy
J. Nucl. Med.,
November 1, 2009;
50(11):
1760 - 1769.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Trimble, J. S. Abrams, R. M. Meyer, F. Calvo, E. Cazap, J. Deye, E. Eisenhauer, T. J. Fitzgerald, D. Lacombe, M. Parmar, et al.
Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials
J. Clin. Oncol.,
October 20, 2009;
27(30):
5109 - 5114.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Delbeke, S. Stroobants, E. de Kerviler, C. Gisselbrecht, M. Meignan, and P. S. Conti
Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma
Oncologist,
October 1, 2009;
14(suppl_2):
30 - 40.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bischof Delaloye, P. S. Conti, C. Gisselbrecht, and S. A. Gregory
Summary
Oncologist,
October 1, 2009;
14(suppl_2):
52 - 54.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Navarro, T. Diaz, A. Martinez, A. Gaya, A. Pons, B. Gel, C. Codony, G. Ferrer, C. Martinez, E. Montserrat, et al.
Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma
Blood,
October 1, 2009;
114(14):
2945 - 2951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Federico, M. Bellei, L. Marcheselli, S. Luminari, A. Lopez-Guillermo, U. Vitolo, B. Pro, S. Pileri, A. Pulsoni, P. Soubeyran, et al.
Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
J. Clin. Oncol.,
September 20, 2009;
27(27):
4555 - 4562.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Schwartz, L. S. Constine, D. Villaluna, W. B. London, R. E. Hutchison, R. Sposto, S. E. Lipshultz, C. S. Turner, P. A. deAlarcon, and A. Chauvenet
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425
Blood,
September 3, 2009;
114(10):
2051 - 2059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Uccella, R Cerutti, C Placidi, S Marchet, I Carnevali, B Bernasconi, I Proserpio, G Pinotti, M G Tibiletti, D Furlan, et al.
MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression
J. Clin. Pathol.,
August 1, 2009;
62(8):
715 - 723.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Rasmussen, L D Sjo, J U Prause, E Ralfkiaer, and S Heegaard
Mantle cell lymphoma in the orbital and adnexal region
Br J Ophthalmol,
August 1, 2009;
93(8):
1047 - 1051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. E. Kohrt, B. B. Turnbull, K. Heydari, J. A. Shizuru, G. G. Laport, D. B. Miklos, L. J. Johnston, S. Arai, W.-K. Weng, R. T. Hoppe, et al.
TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
Blood,
July 30, 2009;
114(5):
1099 - 1109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Markova, C. Kobe, M. Skopalova, K. Klaskova, K. Dedeckova, A. Plutschow, H. T. Eich, M. Dietlein, A. Engert, and T. Kozak
FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value
Ann. Onc.,
July 1, 2009;
20(7):
1270 - 1274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Haioun, N. Mounier, J. F. Emile, D. Ranta, B. Coiffier, H. Tilly, C. Recher, C. Ferme, J. Gabarre, R. Herbrecht, et al.
Rituximab versus observation after high-dose consolidative first-line chemotherapy with autologous stem-cell transplantation in patients with poor-risk diffuse large B-cell lymphoma
Ann. Onc.,
June 30, 2009;
(2009)
mdp237v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Stathis, C. Chini, F. Bertoni, I. Proserpio, C. Capella, L. Mazzucchelli, E. Pedrinis, F. Cavalli, G. Pinotti, and E. Zucca
Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type
Ann. Onc.,
June 1, 2009;
20(6):
1086 - 1093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Vail, D. H. Thamm, H. Reiser, A. S. Ray, G. H.I. Wolfgang, W. J. Watkins, D. Babusis, I. N. Henne, M. J. Hawkins, I. D. Kurzman, et al.
Assessment of GS-9219 in a Pet Dog Model of Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
May 15, 2009;
15(10):
3503 - 3510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
J. Nucl. Med.,
May 1, 2009;
50(Suppl_1):
122S - 150S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hutchings and S. F. Barrington
PET/CT for Therapy Response Assessment in Lymphoma
J. Nucl. Med.,
May 1, 2009;
50(Suppl_1):
21S - 30S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Boellaard
Standards for PET Image Acquisition and Quantitative Data Analysis
J. Nucl. Med.,
May 1, 2009;
50(Suppl_1):
11S - 20S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dreyling and On behalf of the ESMO Guidelines Working Group
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv119 - iv120.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Luigi Zinzani, V. Stefoni, M. Tani, S. Fanti, G. Musuraca, P. Castellucci, E. Marchi, M. Fina, V. Ambrosini, C. Pellegrini, et al.
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
J. Clin. Oncol.,
April 10, 2009;
27(11):
1781 - 1787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Cheson
The Case Against Heavy PETing
J. Clin. Oncol.,
April 10, 2009;
27(11):
1742 - 1743.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bosetti, F. Levi, J. Ferlay, F. Lucchini, E. Negri, and C. La Vecchia
The recent decline in mortality from Hodgkin lymphomas in central and eastern Europe
Ann. Onc.,
April 1, 2009;
20(4):
767 - 774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Esmaeli, P. McLaughlin, B. Pro, F. Samaniego, I. Gayed, F. Hagemeister, J. Romaguera, F. Cabanillas, S. S. Neelapu, R. Banay, et al.
Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma
Ann. Onc.,
April 1, 2009;
20(4):
709 - 714.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura
Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up
Haematologica,
April 1, 2009;
94(4):
550 - 565.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Allen-Auerbach and W. A. Weber
Measuring Response with FDG-PET: Methodological Aspects
Oncologist,
April 1, 2009;
14(4):
369 - 377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. D. Cole, C. L. Schwartz, R. A. Drachtman, P. A. de Alarcon, L. Chen, and T. M. Trippett
Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report
J. Clin. Oncol.,
March 20, 2009;
27(9):
1456 - 1461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Dupuis, E. Itti, A. Rahmouni, F. Hemery, C. Gisselbrecht, C. Lin, C. Copie-Bergman, K. Belhadj, T. El Gnaoui, I. Gaillard, et al.
Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
Ann. Onc.,
March 1, 2009;
20(3):
503 - 507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. de Jong, H. M. Q. van Ufford, H.-J. Baarslag, M. J. de Haas, S. H. Wittebol, L. G. Quekel, and J. M. de Klerk
CT and 18F-FDG PET for Noninvasive Detection of Splenic Involvement in Patients with Malignant Lymphoma
Am. J. Roentgenol.,
March 1, 2009;
192(3):
745 - 753.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Vidal, A. Gafter-Gvili, L. Leibovici, M. Dreyling, M. Ghielmini, S.-F. Hsu Schmitz, A. Cohen, and O. Shpilberg
Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials
J Natl Cancer Inst,
February 18, 2009;
101(4):
248 - 255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S. Han, M. P. Escalon, B. Hsiao, A. Serafini, and I. S. Lossos
High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens
Ann. Onc.,
February 1, 2009;
20(2):
309 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Thomson, E. C. Morris, A. Bloor, G. Cook, D. Milligan, A. Parker, F. Clark, L. Yung, D. C. Linch, R. Chakraverty, et al.
Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
January 20, 2009;
27(3):
426 - 432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tsukasaki, O. Hermine, A. Bazarbachi, L. Ratner, J. C. Ramos, W. Harrington Jr, D. O'Mahony, J. E. Janik, A. L. Bittencourt, G. P. Taylor, et al.
Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting
J. Clin. Oncol.,
January 20, 2009;
27(3):
453 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Ben-Haim and P. Ell
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
J. Nucl. Med.,
January 1, 2009;
50(1):
88 - 99.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl
18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy
J. Nucl. Med.,
January 1, 2009;
50(1):
8 - 17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A E Hallack Neto, S A C Siqueira, F L Dulley, M A Ruiz, D A F Chamone, and J Pereira
p63 Protein expression in high risk diffuse large B-cell lymphoma
J. Clin. Pathol.,
January 1, 2009;
62(1):
77 - 79.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jaccard, B. Petit, S. Girault, F. Suarez, R. Gressin, J.-M. Zini, V. Coiteux, C. Larroche, A. Devidas, C. Thieblemont, et al.
L-Asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature
Ann. Onc.,
January 1, 2009;
20(1):
110 - 116.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Di Nicola, R. Zappasodi, C. Carlo-Stella, R. Mortarini, S. M. Pupa, M. Magni, L. Devizzi, P. Matteucci, P. Baldassari, F. Ravagnani, et al.
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study
Blood,
January 1, 2009;
113(1):
18 - 27.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Lenihan and F. J. Esteva
Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer
Oncologist,
December 1, 2008;
13(12):
1224 - 1234.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Cashen, F. Dehdashti, J. Luo, and N. L. Bartlett
Poor Predictive Value of FDG-PET/CT Performed after 2 Cycles of R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLCL)
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
371 - 371.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
C. Kobe, M. Dietlein, J. Franklin, J. Markova, A. Lohri, H. Amthauer, S. Klutmann, W. H. Knapp, J. M. Zijlstra, A. Bockisch, et al.
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
Blood,
November 15, 2008;
112(10):
3989 - 3994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Devizzi, A. Guidetti, C. Tarella, M. Magni, P. Matteucci, E. Seregni, C. Chiesa, E. Bombardieri, M. Di Nicola, C. Carlo-Stella, et al.
High-Dose Yttrium-90-Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation
J. Clin. Oncol.,
November 10, 2008;
26(32):
5175 - 5182.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Jacobs, S. H. Swerdlow, J. Kant, K. A. Foon, R. Jankowitz, S. R. Land, N. DeMonaco, J. Joyce, J. L. Osborn, T. L. Evans, et al.
Phase II Trial of Short-Course CHOP-R Followed by 90Y-ibritumomab Tiuxetan and Extended Rituximab in Previously Untreated Follicular Lymphoma
Clin. Cancer Res.,
November 1, 2008;
14(21):
7088 - 7094.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Elstrom, J. P. Leonard, M. Coleman, and R. K. J. Brown
Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma
Ann. Onc.,
October 1, 2008;
19(10):
1770 - 1773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A V Martin and B Sharma
Positron emission tomography and CT in the management of lymphoma
Imaging,
September 1, 2008;
20(3):
169 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Bishton, M. F. Leahy, R. J. Hicks, J. H. Turner, A. D. McQuillan, and J. F. Seymour
Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin's lymphoma who had previously responded to iodine-131-rituximab
Ann. Onc.,
September 1, 2008;
19(9):
1629 - 1633.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin,
September 1, 2008;
58(5):
305 - 317.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Zinzani, M. Martelli, V. Poletti, U. Vitolo, P. G. Gobbi, T. Chisesi, G. Barosi, A. J.M. Ferreri, M. Marchetti, N. Pimpinelli, et al.
Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
Haematologica,
September 1, 2008;
93(9):
1364 - 1371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Provencio, I. Millan, P. Espana, A. C. Sanchez, J. J. Sanchez, B. Cantos, J. A. Vargas, C. Bellas, V. Garcia, P. Sabin, et al.
Analysis of Competing Risks of Causes of Death and their Variation Over Different Time Periods in Hodgkin's Disease
Clin. Cancer Res.,
August 15, 2008;
14(16):
5300 - 5305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Arcaini, F. Montanari, E. P. Alessandrino, A. Tucci, E. Brusamolino, L. Gargantini, R. Cairoli, P. Bernasconi, F. Passamonti, M. Bonfichi, et al.
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
Ann. Onc.,
July 1, 2008;
19(7):
1331 - 1335.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek, B. D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Dohner, P. Hillmen, M. J. Keating, E. Montserrat, K. R. Rai, et al.
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Blood,
June 15, 2008;
111(12):
5446 - 5456.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Wilson, K. Dunleavy, S. Pittaluga, U. Hegde, N. Grant, S. M. Steinberg, M. Raffeld, M. Gutierrez, B. A. Chabner, L. Staudt, et al.
Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers
J. Clin. Oncol.,
June 1, 2008;
26(16):
2717 - 2724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Plathow and W. A. Weber
Tumor Cell Metabolism Imaging
J. Nucl. Med.,
June 1, 2008;
49(Suppl_2):
43S - 63S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Schwartz, H. A. Macapinlac, and R. S. Weber
FDG-PET Staging of Head and Neck Cancer--Can Improved Imaging Lead to Improved Treatment?
J Natl Cancer Inst,
May 21, 2008;
100(10):
688 - 689.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Re, S. Ferrari, P. Frata, C. Pizzocaro, C. Crippa, A. Tucci, F. Facchetti, L. Grazioli, S.M. Magrini, and G. Rossi
Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study
Ann. Onc.,
May 1, 2008;
19(5):
951 - 957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Crump, B. Coiffier, E. D. Jacobsen, L. Sun, J. L. Ricker, H. Xie, S. R. Frankel, S. S. Randolph, and B. D. Cheson
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
Ann. Onc.,
May 1, 2008;
19(5):
964 - 969.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bodet-Milin, F. Kraeber-Bodere, P. Moreau, L. Campion, B. Dupas, and S. Le Gouill
Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma
Haematologica,
March 1, 2008;
93(3):
471 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Bodet-Milin, F. Kraeber-Bodere, B. Dupas, F. Morschhauser, T. Gastinne, S. Le Gouill, L. Campion, J.-L. Harousseau, W. A. Wegener, D. M. Goldenberg, et al.
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography
Haematologica,
March 1, 2008;
93(3):
390 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Ulaner, P. M. Colletti, and P. S. Conti
B-Cell Non-Hodgkin Lymphoma: PET/CT Evaluation after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy--Initial Experience
Radiology,
March 1, 2008;
246(3):
895 - 902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya
Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment
Jpn. J. Clin. Oncol.,
January 1, 2008;
38(1):
43 - 48.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Juweid
18F-FDG PET as a Routine Test for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: Where Is the Evidence?
J. Nucl. Med.,
January 1, 2008;
49(1):
9 - 12.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Terasawa, T. Nihashi, T. Hotta, and H. Nagai
18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review
J. Nucl. Med.,
January 1, 2008;
49(1):
13 - 21.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W.M. Johnson and A. J. Davies
Primary Mediastinal B-Cell Lymphoma
Hematology,
January 1, 2008;
2008(1):
349 - 358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. K. Schwarz, B. A. Siegel, F. Dehdashti, and P. W. Grigsby
Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma
JAMA,
November 21, 2007;
298(19):
2289 - 2295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Seam, M. E. Juweid, and B. D. Cheson
The role of FDG-PET scans in patients with lymphoma
Blood,
November 15, 2007;
110(10):
3507 - 3516.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Diehl
Hodgkin's Disease -- From Pathology Specimen to Cure
N. Engl. J. Med.,
November 8, 2007;
357(19):
1968 - 1971.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl
Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
J. Nucl. Med.,
November 1, 2007;
48(11):
1767 - 1776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. A. Weber
18F-FDG PET in Non-Hodgkin's Lymphoma: Qualitative or Quantitative?
J. Nucl. Med.,
October 1, 2007;
48(10):
1580 - 1582.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kako, K. Izutsu, Y. Ota, Y. Minatani, M. Sugaya, T. Momose, K. Ohtomo, Y. Kanda, S. Chiba, T. Motokura, et al.
FDG-PET in T-cell and NK-cell neoplasms
Ann. Onc.,
October 1, 2007;
18(10):
1685 - 1690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani, J. Dupuis, G. Paone, J.-N. Talbot, A. Rahmouni, and M. Meignan
Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis
J. Nucl. Med.,
October 1, 2007;
48(10):
1626 - 1632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Gallamini, M. Hutchings, L. Rigacci, L. Specht, F. Merli, M. Hansen, C. Patti, A. Loft, F. Di Raimondo, F. D'Amore, et al.
Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
J. Clin. Oncol.,
August 20, 2007;
25(24):
3746 - 3752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Robertson, B. S. Kahl, J. M. Vose, S. de Vos, M. Laughlin, P. J. Flynn, K. Rowland, J. C. Cruz, S. L. Goldberg, L. Musib, et al.
Phase II Study of Enzastaurin, a Protein Kinase C Beta Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
May 1, 2007;
25(13):
1741 - 1746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Revised Lymphoma Response Criteria
Journal Watch Oncology and Hematology,
February 16, 2007;
2007(216):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology,
January 1, 2007;
2007(1):
216 - 225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
